Clinical Trials · NCT04001231
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Withdrawn
- Sponsor
- AstraZeneca
- Enrollment
- 0
- Start date
- Jun 2020
- Locations
- See registry
- Primary endpoint
- Plasma concentrations versus time profile of exenatide